

# 3<sup>rd</sup> MIDDLE EAST MASTER CLASS IN HEMATOLOGY

JANUARY 2  
9-10 26



RAFFLES HOTEL  
DUBAI - UAE




9.5





# WELCOME LETTER



Dear Colleagues and Friends,

It is with great enthusiasm that we invite you to the **3<sup>rd</sup> edition of the Middle East Master Class in Hematology (MEMAC)**, held in proud collaboration with the **International Academy for Clinical Hematology (IACH)**. Mark your calendars for **January 9-10, 2026**, and join us at the elegant **Raffles Hotel in Dubai, UAE**.

Hematology remains one of the most rapidly advancing specialties in medicine, driven by breakthroughs in our understanding of disease biology and the rise of innovative therapies, from precision medicine to cutting-edge immunotherapies. In such a fast-paced landscape, coming together to share knowledge and experiences is not just valuable: it is essential.

That is exactly why MEMAC was created: to be a **dedicated platform for hematologists across the region** to explore the latest evidence-based practices in the management of leukemia, lymphoma, multiple myeloma, and more.

Now entering its third year, MEMAC continues to grow in both reach and relevance, offering **rich educational content, expert-led discussions**, and **practical insights** that directly enhance patient care.

We can't wait to welcome you to what promises to be another memorable and impactful gathering in the heart of Dubai, a city known for its energy, hospitality, and innovation.

For updates and further information, please visit [www.memachematology.com](http://www.memachematology.com)

**See you at MEMAC 2026!**



**Ali Bazarbachi, MD, PhD**  
Congress Co-chair



**Mohamad Mohty, MD, PhD**  
Congress Co-chair

The program of the 3<sup>rd</sup> **Middle East Master Class in Hematology (MEMAC) 2026** - from **January 9<sup>th</sup> to 10<sup>th</sup>, 2026**, at **the Raffles Hotel in Dubai, UAE**. has been reviewed and approved for CME accreditation by the European Board of Accreditation in Hematology (EBAH) CME Unit. The EBAH-CME Unit has approved this educational activity for a maximum number of CME credits. Each physician should only claim credits for time that they actually spent in the educational activity. We are pleased to inform you that the 2026 MEMAC has been awarded:



### ***9.5 EBAH-CME Credit Points***

Following the MEMAC Conference, all registered participants will receive a Learner's Questionnaire (LQ). Completion of the LQ is mandatory for CME accreditation. Upon completion, participants will be validated by IACH through the EBAH system and CME credits will be awarded accordingly.







08:00 - 08:30	Registration
08:30 - 09:45	<div><b>Session 1: State-of-the-Art Diagnosis &amp; Therapy in Myeloid Malignancies</b> Moderators: Asma Alolama, MD - Hesham Elsabah, MD - Hanan Hamed, MD - Humaid Al Shamsi, MD</div>
08:30 - 08:50	<div>MDS<div><div></div><div> Amer Zeidan, MD</div></div></div>
08:50 - 09:10	<div>Myelofibrosis<div><div></div><div> Ibrahim Yakoub-Agha, MD</div></div></div>
09:10 - 09:30	<div>CML<div><div></div><div> Giuseppe Saglio, MD</div></div></div>
09:30 - 09:45	<div>Q&amp;A</div>
09:45 - 09:55	<div><div><b>Industry Symposium Novartis</b> <i>Moderator: Mahmoud Marashi, MD - UAE</i></div><div>Key CML Highlights from ASH 2025<div><div></div><div> Inas Elnajjar, MD</div></div></div></div>
09:55 - 10:05	<div>Clinical Experience with SCEMBLIX<div><div></div></div></div>
10:05 - 10:15	<div>Q&amp;A</div>








10:15 - 10:30	<div> Coffee Break</div>	
10:30 - 11:00	<div>Industry Symposium Amgen Blinatumomab in Frontline Adult ALL Consolidation: Evidence and Practice</div>	<div> Emmanouil Nikolousis, MD</div>
11:00 - 12:15	<div>Session 2: Bone Marrow Failures and Gene Therapy Moderators: Magdy Elbordiny, MD - Riad El Fakih, MD - Nour Moukalled, MD - Alaa Alwan, MD</div>	
11:00 - 11:20	<div>Aplastic Anemia</div>	<div> Mahmoud Aljurf, MD</div>
11:20 - 11:40	<div>Gene Therapy in Hemoglobinopathies</div>	<div> Annalisa Ruggeri, MD</div>
11:40 - 11:55	<div> Q&amp;A</div>	
11:55 - 13:35	<div> Lunch &amp; Prayer Break</div>	
13:35 - 14:05	<div>Industry Symposium Johnson &amp; Johnson Advancing CLL Care in 2026: Evidence Updates on BTK Inhibitors and Beyond</div>	<div> Elias Jabbour, MD</div>







14:05 - 14:55	<b>Session 3: State-of-the-Art Diagnosis and Therapy in Chronic Leukemias</b> Moderators: Mahmoud Salah, MD - Shahrukh Hashmi, MD - Faraz Khan, MD - Ghada ElGohary, MD	
14:05 - 14:25	CLL	 Mohamed Kharfan-Dabaja, MD
14:25 - 14:45	Hairy Cell Leukemia	 Mervat Mattar, MD
14:45 - 14:55	 Q&A	
14:55 - 15:15	<b>Industry Symposium Gilead Kite</b> Reshaping R/R DLBCL Care with Potentiality to Cure - CART Role	 Emmanouil Nikolousis, MD
15:15 - 15:35		



15:35 - 16:25	<b>Session 4: State-of-the-Art Diagnosis and Treatment of Acute Lymphoblastic Leukemia</b> Moderators: Husam Abu Jazar, MD - Ahmad Ibrahim, MD - Nabil Yafour, MD - Mahmoud Marashi, MD	
15:35 - 15:55	T-ALL	 Eolia Brissot, MD
15:55 - 16:15	B-ALL	 Elias Jabbour, MD
16:15 - 16:25	 Q&A	
16:25 - 17:25	<b>Industry Symposium Roche</b> Transforming the Second Line Landscape in DLBCL with STARGLO	 William Townsend, MD
17:25 - 17:40	 <b>Coffee Break</b>	



17:40 - 18:10	<b>Session 5: Plenary Session</b> Moderators: Ali Bazarbachi, MD - Mohamad Mohty, MD	
17:40 - 18:05	CAR T Cells: Past, Present & Future	 Michel Sadelain, MD
18:05 - 18:10	🗨️ Q&A	
<b>SESSION 6: Plenary Session</b> Moderators: Khalid Halahleh, MD - Iman Abou Dalle, MD - Shabeeha Rana, MD - Malek Benakli, MD		
18:10 - 18:40		
18:10 - 18:35	Modern Therapy of AML	 Hagop Kantarjian, MD
18:35 - 18:40	🗨️ Q&A	
18:40	Closing	





08:00 - 08:30	Registration	
08:30 - 09:45	<b>Session 7: State-of-the-Art Diagnosis &amp; Therapy in Lymphoma - 1</b> Moderators: Bassim Albeirouti, MD - Inas Al Najjar, MD - Honar Cherif, MD	
08:30 - 08:50	DLBCL	Anna Sureda, MD
08:50 - 09:10	T NHL	Laurent Gandhi Damaj, MD
09:10 - 09:30	Relapsed Hodgkin Lymphoma	Ali Bazarbachi, MD
09:30 - 09:45	🗣️ Q&A	
09:45 - 10:15	<b>Industry Symposium Astellas</b> Beyond the Horizon: Optimizing the Management of FLT3mut+ R/R AML: The Role of Gilteritinib	Mark Levis, MD
10:15 - 10:45	<b>Industry Symposium Johnson &amp; Johnson</b> Front-line Multiple Myeloma: Redefining standard of care	Meletios Dimopoulos, MD
10:45 - 11:15	Relapsed Multiple Myeloma: Innovations in Therapy and Care Pathways	Ali Bazarbachi, MD








11:15 - 11:30	<div>Coffee Break</div>	
11:30 - 11:50	<div>Industry Symposium Abbvie</div> <div>BsAbs: a New Era in Lymphoma Management</div>	<div>Emmanouil Nikolousis, MD</div>
11:50 - 12:10	<div>Industry Symposium Takeda</div> <div>Moderator: Ali Bazarbachi, MD</div> <div>HD21 and the Future of Hodgkin Lymphoma</div>	<div>Anna Sureda, MD</div>
12:10 - 12:30	<div>Shaping Frontline Treatment in HL: Expert Perspectives and Future Direction</div>	<div>Anna Sureda, MD</div> <div>Salem Alshemmari, MD</div> <div>Arif Alam, MD</div>
12:30 - 13:40	<div>Session 8: State-of-the-Art Diagnosis &amp; Therapy in Lymphoma - 2</div> <div>Moderators: Ajlan Al Zaki, MD - Colette Hanna, MD - Ibrahim Abu Gheida, MD - Rasha Galal, MD</div>	
12:30 - 12:50	<div>Mantle Cell Lymphoma</div>	<div>Olivier Hermine, MD</div>
12:50 - 13:10	<div>Low Grade Lymphoma</div>	<div>Reyad Dada, MD</div>
13:10- 13:30	<div>Waldenstrom Disease</div>	<div>Meletios Dimopoulos, MD</div>
13:30 - 13:40	<div>Q&amp;A</div>	



13:40 - 14:00	<div>Industry Symposium GSK</div> <div>Elevating the Outcomes in RRMM: A New Era</div>	<div><div></div><div>Mohamad Mohty, MD</div></div>
14:00 - 15:00	<div><div></div><div>Lunch Break</div></div>	
15:00 - 15:45	<div>Industry Symposium Sanofi</div> <div>Moderator: Ahmad Alsaeed, MD - KSA</div> <div>Evolution in Multiple Myeloma Treatment: From Triplets to Quadruplet Regimens</div>	<div><div></div><div>Ghazi Alotaibi, MD</div></div>
15:45 - 16:30	<div>Moderator: Mahmoud Marashi, MD - UAE</div> <div>The Role of MRD Negativity Testing in Multiple Myeloma Management</div>	<div><div></div><div>Ayman Alhejazi, MD</div></div>
		<div><div></div><div>Ahmad Alhuraiji, MD</div></div>
		<div><div></div><div>Saud Alhayli, MD</div></div>
16:30 - 16:45	<div><div></div><div>Coffee Break</div></div>	
16:45 - 17:05	<div>Industry Symposium Sandoz</div> <div>TBA</div>	





17:05 - 17:55	<b>Session 9: State-of-the-Art Diagnosis and Treatment of Multiple Myeloma</b> Moderators: Mohamad Azzam Ziade, MD - Murthada Al Khabori, MD - Tazi Mazalek Zoubida, MD	
17:05 - 17:25	Newly Diagnosed Multiple Myeloma	<div></div>  Thierry Facon, MD
17:25 - 17:45	New Saudi Guidelines for Myeloma	<div></div>  Ghazi Alotaibi, MD
17:45 - 17:55	<div></div> Q&A	
17:55 - 18:25	<b>Session 10: Acute Leukemia Clinical Cases</b> Moderators: Ahmed Alaskar, MD - Jean El Cheikh, MD - Nour Ben Abdeljelil, MD	
17:55 - 18:10	Clinical Case 1	<div></div> TBC <div></div>  Mohammad Bakkar, MD
18:10 - 18:25	Clinical Case 2	
18:25 - 18:55	<b>Session 11: Lymphoma Clinical Cases</b> Moderators: Mohamad Mohty, MD - Ali Bazarbach, MD - Muna Altarshi, MD	
18:25 - 18:40	Clinical Case 1	<div></div>  Kayane Mheidly, MD
18:40 - 18:55	Clinical Case 2	<div></div>  Marwa Tagelsir Ahmed, MD
18:55	Closing	

sanofi

Johnson & Johnson  
Innovative Medicine



ORGANIZED BY:



UAE | Lebanon | Kuwait | Iraq